Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc. | Ifetroban | Portal hypertension | Phase 2 | Trial Completed | Oral | Gastroenterology |
| CureVac N.V. | CV0601 | COVID-19 vaccine | Phase 2 | Data Released | Intravenous | COVID-19 |
| CureVac N.V. | CVnCoV | COVID-19 vaccine | Phase 2/3 | Withdrawn | Intramuscular | COVID-19 |
| CureVac N.V. | Multivalent seasonal influenza vaccine | Influenza B strain | Phase 2 | Data Released | Intramuscular | Antiviral |
| Curis Inc. | CA-4948 - (TakeAim Lymphoma) | Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 2 | Ongoing | Oral | Oncology |
| Cybin Inc. | CYB003 - (APPROACH) | Major depressive disorder (MDD) | Phase 3 | Ongoing | Oral | Psychiatric |
| Cybin Inc. | CYB003 - (EXTEND and EMBRACE) | Major Depressive Disorder (MDD) and Alcohol use disorder (AUD) | Phase 2 | Data Released | Oral | Psychiatric |
| Cybin Inc. | Psilocybin - (EMBARK) | Mental distress in healthcare workers | Phase 2 | Trial Planned | Oral | Psychiatric |
